Trials / Conditions / Acute Lymphoblastic Leukemia, Adult

Acute Lymphoblastic Leukemia, Adult

20 registered clinical trials studyying Acute Lymphoblastic Leukemia, Adult — 14 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblasti NCT07495631	Institute of Hematology & Blood Diseases Hospital, China	N/A
Recruiting	Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL NCT07059156	Shanxi Bethune Hospital	Phase 2 / Phase 3
Recruiting	A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI NCT06564545	The First Affiliated Hospital of Zhengzhou University	Phase 2
Recruiting	A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI C NCT06557161	The First Affiliated Hospital of Zhengzhou University	Phase 2
Recruiting	CAR T-cell Therapy in Patients With Renal Dysfunction NCT05909059	Northside Hospital, Inc.	Phase 2
Recruiting	Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL NCT06481241	Institute of Hematology & Blood Diseases Hospital, China	N/A
Recruiting	Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ NCT06481228	Institute of Hematology & Blood Diseases Hospital, China	N/A
Recruiting	Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO NCT06025682	Gruppo Italiano Malattie EMatologiche dell'Adulto	—
Recruiting	Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine NCT06060782	Fifth Affiliated Hospital, Sun Yat-Sen University	Phase 1
Recruiting	TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies NCT06206174	Shenzhen TargetRx Co., Ltd.	Phase 1 / Phase 2
Withdrawn	High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD NCT05895201	Indiana University	Phase 1 / Phase 2
Recruiting	Determining the Mechanisms of Loss of CAR T Cell Persistence NCT05809284	University College, London	—
Recruiting	Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative NCT05750706	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	—
Recruiting	RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL NCT05127148	Grupo Argentino de Tratamiento de la Leucemia Aguda	—
Terminated	Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL NCT04554459	Institute of Hematology and Blood Transfusion, Czech Republic	Phase 2
Unknown	Study in Adult Ph-positive ALL NCT04688983	Cardiff University	Phase 2
Withdrawn	Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab NCT03982992	Ludwig-Maximilians - University of Munich	Phase 2
Unknown	Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia NCT03339700	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	Phase 2
Recruiting	Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-gener NCT03676504	University Hospital Heidelberg	Phase 1 / Phase 2
Terminated	International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic NCT03705507	University of Birmingham	Phase 1 / Phase 2